2013-02-14 20:22:31 - Recently published research from Espicom Business Intelligence, "Olympus Medical Device Company Intelligence Report", is now available at Fast Market Research

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.
Olympus Corporation, headquartered in Tokyo, Japan, develops and manufactures products based on optical and electronic technology for the consumer, scientific, healthcare and industrial markets. The company operates within five divisions; Medical, Imaging, Life Science & Industrial, Information & Communication and Other.


Full Report Details at

- www.fastmr.com/prod/538095_olympus_medical_device_company_intell ..


The main focus of this profile is Olympus Medical, the Olympus group’s largest operating division, accounting for almost 41% of the company’s total turnover in the financial year ended 31st March 2012. The division is a leading manufacturer of gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and related products.

Olympus Medical sells its products throughout the world and has manufacturing facilities in Japan, the US, Germany, the UK, the Czech Republic and Vietnam. In fiscal year 2012, the division generated net sales of ¥349.2 billion.

In October 2011, Olympus was embroiled in a global scandal, when it emerged that the company had participated in fraudulent long-term loss-hiding activities. The activities were uncovered by the company’s then new CEO, Michael Woodford, who raised questions over suspect acquisitions Olympus had made outside of its core business, as well as disproportionately high M&A fees associated with them. Of particular suspicion was the February 2008 acquisition of Gyrus ACMI, which carried a US$687 million middle-man fee, a sum equal to 31% of the purchase price.

On 14th October 2011, Woodfood was sacked as Olympus’ CEO by the company’s Board of Directors, allegedly over Woodford’s insistence that the Olympus officials come clean about the series of questionable acquisitions totalling US$1.6 billion. The deals had been approved by Woodford’s predecessor, Tsuyoshi Kikukawa Kikukawa, as well as the Olympus Board, but in several cases, the parties receiving the sums were not identified in Olympus’ financial statements. Woodford was replaced by Kikukawa, but on 26th October 2011, Kikukawa resigned, to be replaced by new President, Hiroyuki Sasa. On 8th November 2011, Olympus was forced to admit that its accounting practices had been used to conceal losses, dating back to the 1990s. Kikukawa was blamed, along with the company’s auditor and an Executive Vice President.

Partial Table of Contents:

OVERVIEW
STRATEGIC FOCUS
Corporate Management Policies
Basic Strategies
Rebuilding of the Business Portfolio and Optimal Allocation of Management Resources
Review of Cost Structures
Restoration of Financial Health
Restructuring of Governance
Performance Indices and Targets
Analysis of Japanese Medical Market
FINANCIAL REVIEW
Fiscal 2012 Financial Results
Medical Products Division
Five-Year Financial Data
Employees
Outlook
PRODUCTS
Endoscopic and Surgical Products
Cleaning, Disinfecting and Sterilisation
Endotherapy Products
Energy and Tissue Management
Biotechnology
Dental Products
Healthcare IT Products
EndoWorks Information Management System
Endobase Endoscopy Management and Image Filing System
Solemio Support Systems
n-Stream Dual Channel Video Management System
VaultStream
RESEARCH AND DEVELOPMENT
R&D Establishments
R&D Agreements
Siemens Healthcare
Cytori Therapeutics
Terumo
Heart Surgery
Gastroenterology
Urology
Cleveland Clinic Glickman Urological Institute
R&D Expenditure
MANUFACTURING AND DISTRIBUTION
Manufacturing
Sales and Distribution
AGREEMENTS
BonAlive Biomaterials
Carl Zeiss Microscopy
Caris Diagnostics
DigiPath
Leica Microsystems
Hirox-USA
SBi APAC
Advanced Surgical Concepts
BrainLAB
Aloka
MERGERS AND ACQUISITIONS
Spirus Medical
Stryker’s OP-1 Business
Innov-X Systems
Spiration
Olympus Surgical Technologies Europe
Iwaken
Merger of Olympus’ UK Businesses
Gyrus
MINORITY INVESTMENTS
Small Bone Innovations
Cytori Therapeutics
Asthmatx
AJ Industries
Terumo
JOINT VENTURES
Sony-Olympus Medical Solutions
Olympus Terumo Biomaterials
Olympus-Cytori
LITIGATION
Class Action Lawsuit
Terumo
Given Imaging
KEY CORPORATE EVENTS
List of Tables
Recent Key Events
Olympus – Performance Indices and Targets to FY2017
Espicom Analysis of Japanese Medical Market, 2012
Olympus - Annual Financial Results, FY2008-FY2012
Olympus - Annual Sales by Business Segment, FY2008-FY2012
Olympus Medical - Annual Financial Results, FY2008-FY2012
Olympus Medical - Annual Sales by Product Area, FY2008-FY2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=538095&dt=t

About Espicom Business Intelligence

Espicom Business Intelligence is a highly-regarded and established provider of business intelligence services. Founded in 1982 as MDIS Publications Ltd, the company changed its name to Espicom in 1992. Initially a publisher in a wide range of industries such as power generation and telecommunications, they now focus on the global pharmaceutical and medical device sectors. View more research from Espicom Business Intelligence at www.fastmr.com/catalog/publishers.aspx?pubid=1025

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.